Page 171 - Aet News Today

Physicians face a lot of barriers from insurers in completing studies on drugs in the accelerated approval pathway, declared Dr. Robert Califf, commissioner of food and drugs at the Food and Drug Administration. Insurers need to help, he said during the AHIP Medicare, Medicaid, Duals and Commercial Markets Forum. 

The FDA is apparently open to new technologies that enable patients to easily participate in clinical research, whether it be from their homes, a nearby clinic, or a provider’s office.

Violence against healthcare workers is a rising concern as hospitals struggle to retain and add staff. Don't miss the compelling discussion on the root causes of this violence and what's being done about it.

Our challenges in the health space are too daunting for any single organization to tackle alone. We need to draw from both the strengths of the incumbents and the start-ups that have emerged in recent years, whether the challenge is in navigating care, simplifying care delivery, or fostering stronger patient engagement.

During an interview at the AHIP Medicare, Medicaid, Duals and Commercial Markets Forum held Tuesday in Washington, D.C., CMS Administrator Chiquita Brooks-LaSure discussed CMS' key focus areas for 2023. This includes the end of the public health emergency, health equity and prescription drug costs.

When it comes to heart health, time is of the essence. ECGs are considered the most reliable tools, but only if they are continuous and long-term in nature. Continuous Heart Rhythm Monitoring is simply the only solution for prevention and/or management for the number one global health issue.

Pfizer is no stranger to antibody drug conjugate cancer therapies, but it hasn’t been commercially successful with them. The pharma giant’s agreement to acquire Seagen for $43 billion will thrust it to the forefront of the ADC drug class, which has become a hot space for research and regulatory activity in recent years.

Companies who raised drug prices higher than the rate of inflation must rebate the difference to Medicare, according to a provision of the Inflation Reduction Act. The highest-profile product on the list might be AbbVie’s blockbuster immunology drug Humira.

Virtual care company TytoCare has received FDA clearance for its wheeze detection algorithm, allowing the company to begin commercializing the product in the U.S. The new algorithm is an expansion of Tyto Insights, the company's AI-powered diagnosis support software.

ChristianaCare, a health system with headquarters in Delaware, recently launched a direct-to-consumer virtual primary care practice. The new service, which operates on a subscription model, was rolled out to help increase access to round-the-clock, convenient primary care. It's currently offered in six states.